As of 2024-12-12, the Relative Valuation of Kinnate Biopharma Inc (KNTE) is (55.46) USD. This relative valuation is based on P/E multiples. With the latest stock price at 2.65 USD, the upside of Kinnate Biopharma Inc based on Relative Valuation is -2193.0%.
The range of the Relative Valuation is (51.87) - (48.38) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 21.7x - 31.7x | 26.7x |
| Forward P/E multiples | 19.2x - 20.3x | 19.8x |
| Fair Price | (51.87) - (48.38) | (55.46) |
| Upside | -2057.4% - -1925.8% | -2193.0% |
| Date | P/E |